Proteome analysis of in vitro and in vivo root tissue of Withania somnifera

2011 ◽  
Vol 10 (74) ◽  
Author(s):  
Kalaiselvi Senthil,
Keyword(s):  
Withania Somnifera ◽  
Proteome Analysis ◽  
Root Tissue

In vivo and in vitro Variation in Protein Profiling in Withania somnifera (L.) Dunal

2014 ◽  
Vol 8 (2) ◽  
pp. 25-34
Author(s):  
Pallavi Sharma ◽  
Ankita Yadav ◽  
Richa Bhardwaj ◽  
R.A. Sharma
Keyword(s):  
Withania Somnifera ◽  
Protein Profiling

Withania somnifera aqueous extract facilitates the expression and release of GnRH: In vitro and in vivo study

2015 ◽  
Vol 89 ◽  
pp. 111-119 ◽  
Author(s):  
Hardeep Kataria ◽  
Muskan Gupta ◽  
Sukhwinder Lakhman ◽  
Gurcharan Kaur
Keyword(s):  
Aqueous Extract ◽  
Withania Somnifera ◽  
In Vivo Study

scholarly journals Withania somnifera (L.) Dunal: Opportunity for Clinical Repurposing in COVID-19 Management

2021 ◽  
Vol 12 ◽  
Author(s):  
Akash Saggam ◽  
Kirti Limgaokar ◽  
Swapnil Borse ◽  
Preeti Chavan-Gautam ◽  
Santosh Dixit ◽  
...  
Keyword(s):  
Viral Entry ◽  
Clinical Studies ◽  
Withania Somnifera ◽  
Viral Infections ◽  
H1n1 Influenza ◽  
Modern Medicine ◽  
Noncommunicable Diseases ◽  
Organ Protection

As the COVID-19 pandemic is progressing, the therapeutic gaps in conventional management have highlighted the need for the integration of traditional knowledge systems with modern medicine. Ayurvedic medicines, especially Ashwagandha (Withania somnifera (L.) Dunal, WS), may be beneficial in the management of COVID-19. WS is a widely prescribed Ayurvedic botanical known as an immunomodulatory, antiviral, anti-inflammatory, and adaptogenic agent. The chemical profile and pharmacological activities of WS have been extensively reported. Several clinical studies have reported its safety for use in humans. This review presents a research synthesis of in silico, in vitro, in vivo, and clinical studies on Withania somnifera (L.) Dunal (WS) and discusses its potential for prophylaxis and management of COVID-19. We have collated the data from studies on WS that focused on viral infections (HIV, HSV, H1N1 influenza, etc.) and noncommunicable diseases (hypertension, diabetes, cancer, etc.). The experimental literature indicates that WS has the potential for 1) maintaining immune homeostasis, 2) regulating inflammation, 3) suppressing pro-inflammatory cytokines, 4) organ protection (nervous system, heart, lung, liver, and kidney), and 5) anti-stress, antihypertensive, and antidiabetic activities. Using these trends, the review presents a triangulation of Ayurveda wisdom, pharmacological properties, and COVID-19 pathophysiology ranging from viral entry to end-stage acute respiratory distress syndrome (ARDS). The review proposes WS as a potential therapeutic adjuvant for various stages of COVID-19 management. WS may also have beneficial effects on comorbidities associated with the COVID-19. However, systematic studies are needed to realize the potential of WS for improving clinical outcome of patients with COVID-19.

scholarly journals Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16

Gut ◽  
2020 ◽  
pp. gutjnl-2020-321187
Author(s):  
Songhe Guo ◽  
Jun Chen ◽  
Fangfang Chen ◽  
Qiuyao Zeng ◽  
Wan-Li Liu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumour Progression ◽  
Proteome Analysis ◽  
Fusobacterium Nucleatum ◽  
Tumour Cells ◽  
Migration Ability ◽  
Tumour Metastasis ◽  
Infected Cells

ObjectiveExosomes released from tumour cells are packed with unique RNA and protein cargo, and they are emerging as an important mediator in the communication network that promotes tumour progression. The facultative intracellular bacterium Fusobacterium nucleatum (Fn) is an important colorectal cancer (CRC)-associated bacterium. To date, the function of exosomes from Fn-infected CRC cells has not been explored.DesignExosomes were isolated by sequential differential centrifugation and verified by transmission electron microscopy, NanoSight analysis and Western blotting. Given that exosomes have been shown to transport miRNAs and proteins to alter cellular functions, we performed miRNA sequencing and proteome analysis of exosomes from Fn-infected and non-infected cells. The biological role and mechanism of exosomes from Fn-infected cells in CRC tumour growth and liver metastasis were determined in vitro and in vivo.ResultsWe demonstrated that exosomes delivered miR-1246/92b-3p/27a-3p and CXCL16/RhoA/IL-8 from Fn-infected cells into non-infected cells to increase cell migration ability in vitro and promote tumour metastasis in vivo. Finally, both circulating exosomal miR-1246/92b-3p/27a-3p and CXCL16 levels were closely associated with Fn abundance and tumour stage in patients with CRC.ConclusionThis study suggests that Fn infection may stimulate tumour cells to generate miR-1246/92b-3p/27a-3p-rich and CXCL16/RhoA/IL-8 exosomes that are delivered to uninfected cells to promote prometastatic behaviours.

scholarly journals A COMPARATIVE STUDY OF THE ANTI-OXIDATIVE AND ANTI-DIABETIC POTENTIAL OF IN VITRO AND IN VIVO ROOT AND LEAF EXTRACTS OF WITHANIA SOMNIFERA ON STREPTOZOTOCIN INDUCED DIABETIC RATS

2016 ◽  
Vol 8 (10) ◽  
pp. 85 ◽  
Author(s):  
Somanatha Jena ◽  
Ram C. Jena ◽  
Rasmita Bhol ◽  
Khusbu Agarwal ◽  
Ansuman Sarangi ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Withania Somnifera ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Diabetic Rats ◽  
Root Extract ◽  
Leaf Extracts ◽  
Root Extracts

<p><strong>Objective: </strong>The present investigation explores the possibilities of using the <em>in vitro</em> and <em>in vivo </em>root and leaf extracts of <em>Withania somnifera </em>for anti-diabetic and anti-hyperlipidaemic effects on streptozotocin-induced diabetic rats.</p><p><strong>Methods: </strong><em>In vitro </em>shoot cultures of <em>Withania somnifera</em> were raised by the axillary proliferation in nodal explants from a garden grown plant using Murashige and Skoog medium then <em>in</em><em> vitro</em> raised roots and shoots were used for the anti-hyperglycemic and anti-hyperlipidaemic experiment. After 72 h of STZ administration, the fasting blood glucose levels were measured and the rats showing FBG level&gt;220 mg/dl were considered to be diabetic and were used for the hyperglycemic study. <em>In vitro</em> and <em>in vivo</em> methanolic root and leaf extracts were orally administered daily to diabetic rats for eight weeks. After the treatment period, blood glucose and serum enzymes like aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), total cholesterol, triglycerides, HDL-c high density lipoprotein-bound cholesterol, LDL-c low density lipoprotein-bound cholesterol, LDH, serum protein level, total phenolics and anti-oxidative analysis (DPPH and FRAP) were determined.</p><p><strong>Results: </strong>The levels of blood glucose, AST, ALT, ALP, LDH, HDL-c significantly increased by the use of <em>in vitro</em> methanolic root extracts compared to normal control rats. However, remarkable loss of total protein, albumin, albumin: globulin (A: G) ratio was reported in streptozotocin-induced diabetic rats by using <em>in vitro</em> root extracts. Methanolic <em>in vitro</em> root extract at the dose levels of 300 mg/kg body weight produced a significant decrease in fasting blood glucose (FBG) level by 102.65 with respect to initial fasting blood glucose level after 30 d of the treatment. <em>In vitro</em> root extract demonstrated highest DPPH and FRAP free radical scavenging activity, i.e. 86.55±1.77 and 48.87±2.55 than other extracts.</p><p><strong>Conclusion: </strong>It may be concluded that methanolic <em>in vitro</em> root extract <em>W. somnifera </em>at the dose (300 mg/kg) has more potent anti-hyperglycaemic activity than the other <em>in vitro</em> and <em>in vivo </em>extracts of leaf and root on streptozotocin induced diabetic rats and was also found to be similar in effect to that of the standard drug ‘Glibenclamide’.</p>

scholarly journals Withaferin A—A Promising Phytochemical Compound with Multiple Results in Dermatological Diseases

Molecules ◽  
2021 ◽  
Vol 26 (9) ◽  
pp. 2407
Author(s):  
Simona Bungau ◽  
Cosmin Mihai Vesa ◽  
Areha Abid ◽  
Tapan Behl ◽  
Delia Mirela Tit ◽  
...  
Keyword(s):  
Mechanism Of Action ◽  
In Silico ◽  
Withania Somnifera ◽  
In Vivo Studies ◽  
Withaferin A ◽  
Biological Targets ◽  
Dermatological Diseases ◽  
Anticancer Effects

Withaferin A (WFA) was identified as the most active phytocompound of the plant Withania somnifera (WS) and as having multiple therapeutic/ameliorating properties (anticancer, antiangiogenic, anti-invasive, anti-inflammatory, proapoptotic, etc.) in case of various diseases. In drug chemistry, WFA in silico approaches have identified favorite biological targets, stimulating and accelerating research to evaluate its pharmacological activity—numerous anticancer effects manifested in various organs (breast, pancreas, skin, colon, etc.), antivirals, anti-infective, etc., which are not yet sufficiently explored. This paper is a synthesis of the most relevant specialized papers in the field that are focused on the use of WFA in dermatological diseases, describing its mechanism of action while providing, at the same time, details about the results of its testing in in vitro/in vivo studies.

Sign in / Sign up

Export Citation Format

Share Document